A small prospective COPD study reported numerical decreases in serum MMP-9 with roflumilast alongside clinical improvement (CAT score), although changes did not reach statistical significance-underscoring limited power and substantial biomarker variability [ 103 ].
← all excerpts
Matrix Metalloproteinase-9 (MMP-9) as a Therapeutic Target: Insights into Molecular Pathways and Clinical Applications.
1
—
—